St. Jude buys Nanostim for $123.5M

Candace Stuart | | Cardiovascular Business | Heart Rhythm

St. Jude Medical acquired Nanostim, a developer of miniaturized leadless pacemakers, for $123.5 million after a two-year partnership with the company.

Nanostim’s leadless pacemaker received CE Mark in Europe and conditional approval from the FDA to test the product. The small leadless pacemaker is delivered via a catheter in the femoral vein to the heart. The device is retrievable to replace the battery or reposition it during delivery.

The agreement includes a $65 million cash payment to Milpitas, Calif.-based Nanostim, contingent on meeting defined milestones. St. Jude is based in St. Paul, Minn.

Candace Stuart, Contributor

Related Content

Johnson & Johnson pauses use of FDA-approved PFA system to investigate patient complications
History made: Young child treated with new heart device for very first time
ACC offers practical approaches for arrhythmia monitoring after stroke
FDA announces recall of cryoablation catheters after multiple injuries, including 4 deaths
Cardiologists perform world’s first leadless LBBAP procedures with Abbott pacemaker
President of medical device company resigns over conduct allegations after 7 months in role

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.